Reference health
Maltol‐Derived Ruthenium–Cymene Complexes with Tumor Inhibiting Properties: The Impact of Ligand–Metal Bond Stability on Anticancer Activity In Vitro
48/48 checkable references clean · checked 2026-07-25
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 48 checked references that resolve
resolves10.1016/j.drup.2008.02.002
Resistance against novel anticancer metal compounds: Differences and similarities
resolves10.1002/ejic.200600723
Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy
resolves10.1039/B707077M
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
resolves10.1158/1078-0432.CCR-03-0746
A Phase I and Pharmacological Study with Imidazolium-<b>
<i>trans-</i>
</b>DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
resolves10.1002/cbdv.200890195
KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
resolves10.1016/j.jinorgbio.2006.02.013
From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
resolves10.1002/asia.200800149
Medicinal Organometallic Chemistry: Designing Metal Arene Complexes as Anticancer Agents
resolves10.1039/b309160k
Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy
resolves10.1039/b508060f
Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(iii) compound with plasma proteins
resolves10.1039/B511792E
Redox behavior of tumor-inhibiting ruthenium(
<scp>iii</scp>
) complexes and effects of physiological reductants on their binding to GMP
resolves10.1021/jm0490742
Redox-Active Antineoplastic Ruthenium Complexes with Indazole: Correlation of in Vitro Potency and Reduction Potential
resolves10.1002/elps.200780790
Capillary electrophoresis hyphenated to inductively coupled plasma‐mass spectrometry: A novel approach for the analysis of anticancer metallodrugs in human serum and plasma
resolves10.1039/b104021a
[Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells
resolves10.1002/chem.200601152
Osmium(II) and Ruthenium(II) Arene Maltolato Complexes: Rapid Hydrolysis and Nucleobase Binding
resolves10.1021/ja017482e
Organometallic Ruthenium(II) Diamine Anticancer Complexes: Arene-Nucleobase Stacking and Stereospecific Hydrogen-Bonding in Guanine Adducts
resolves10.1016/j.bcp.2008.10.021
DNA interactions of dinuclear RuII arene antitumor complexes in cell-free media
resolves10.1002/chem.200400640
Use of Chelating Ligands to Tune the Reactive Site of Half‐Sandwich Ruthenium(<scp>II</scp>)–Arene Anticancer Complexes
resolves10.2533/chimia.2007.698
Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-clinical Development
resolves10.1007/s00775-008-0400-9
The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways
resolves10.1038/sj.bjc.6600290
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer
resolves10.1021/jm060596m
Structure−Activity Relationships for Cytotoxic Ruthenium(II) Arene Complexes Containing N,N-, N,O-, and O,O-Chelating Ligands
resolves10.1021/ic061008y
Development of Organometallic Ruthenium−Arene Anticancer Drugs That Resist Hydrolysis
resolves10.1021/om800207t
Influence of the Spacer Length on the <i>in Vitro</i> Anticancer Activity of Dinuclear Ruthenium−Arene Compounds
resolves10.1002/aoc.1394
Modifying the structure of dinuclear ruthenium complexes with antitumor activity
resolves10.1021/om800774t
Water-Soluble Mixed-Ligand Ruthenium(II) and Osmium(II) Arene Complexes with High Antiproliferative Activity
resolves10.1016/j.jorganchem.2008.10.016
Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety
resolves10.1021/jm8013234
Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer Activity
resolves10.1021/om900483t
From Pyrone to Thiopyrone Ligands−Rendering Maltol-Derived Ruthenium(II)−Arene Complexes That Are Anticancer Active in Vitro
resolves10.1016/j.jorganchem.2008.11.026
Organometallic complexes that interconvert between trimeric and monomeric structures as a function of pH and their effect on human cancer and fibroblast cells
resolves10.1039/b416256k
Metal complexes of maltol and close analogues in medicinal inorganic chemistry
resolves10.1021/jm991080o
Synthesis, Physicochemical Characterization, and Biological Evaluation of 2-(1‘-Hydroxyalkyl)-3-hydroxypyridin-4-ones: Novel Iron Chelators with Enhanced pFe<sup>3+</sup> Values
resolves10.1016/S0020-1693(99)00280-7
Halfsandwich complexes of ruthenium(II), rhodium(III) and iridium(III) with N-substituted 3-hydroxy-2-methyl-4-pyridone ligands
resolves10.1002/chem.200801032
In Vitro Anticancer Activity and Biologically Relevant Metabolization of Organometallic Ruthenium Complexes with Carbohydrate‐Based Ligands
resolves10.1016/j.jinorgbio.2007.10.016
Studies on the reactivity of organometallic Ru–, Rh– and Os–pta complexes with DNA model compounds
resolves10.1107/S0021889897003117
<i>ORTEP</i>-3 for Windows - a version of<i>ORTEP</i>-III with a Graphical User Interface (GUI)
resolves10.1016/j.jinorgbio.2003.10.001
A formula for correlating p K a values determined in D 2 O and H 2 O
resolves10.1103/PhysRevB.37.785
Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density
resolves10.1007/BF01114537
Energy-adjustedab initio pseudopotentials for the second and third row transition elements
resolves10.1021/cr00031a013
Molecular Interactions in Solution: An Overview of Methods Based on Continuous Distributions of the Solvent
resolves10.1021/jp9716997
Quantum Calculation of Molecular Energies and Energy Gradients in Solution by a Conductor Solvent Model
The 6 references without a DOI — listed, not checked
no DOI — not checkedBioorganometallics
no DOI — not checkedSAINT + Integration Engine Program for Crystal Structure Integration M. R. Pressprich J. Chambers Bruker Analytical X‐ray systems Madison 2004.
no DOI — not checkedSHELXS‐97 Program for Crystal Structure Solution G. M. Sheldrick Göttingen (Germany) 1997.
no DOI — not checkedSHELXL‐97 Program for Crystal Structure Refinement G. M. Sheldrick Göttingen (Germany) 1997.
no DOI — not checkedInternational Tables for X‐ray Crystallography, Vol. C
no DOI — not checkedGaussian 03 Revision D.01 M. J. Frisch G. W. Trucks H. B. Schlegel G. E. Scuseria M. A. Robb J. R. Cheeseman J. Montgomery Jr. J. A. T. Vreven K. N. Kudin J. C. Burant J. M. Millam S. S. Iyengar J. Tomasi V. Barone B. Mennucci M. Cossi G. Scalmani N. Rega G. A. Petersson H. Nakatsuji M. Hada M. Ehara K. Toyota R. Fukuda J. Hasegawa M. Ishida T. Nakajima Y. Honda O. Kitao H. Nakai M. Klene X. Li J. E. Knox H. P. Hratchian J. B. Cross V. Bakken C. Adamo J. Jaramillo R. Gomperts R. E. Stratmann O. Yazyev A. J. Austin R. Cammi C. Pomelli J. W. Ochterski P. Y. Ayala K. Morokuma G. A. Voth P. Salvador J. J. Dannenberg V. G. Zakrzewski S. Dapprich A. D. Daniels M. C. Strain O. Farkas D. K. Malick A. D. Rabuck K. Raghavachari J. B. Foresman J. V. Ortiz Q. Cui A. G. Baboul S. Clifford J. Cioslowski B. B. Stefanov G. Liu A. Liashenko P. Piskorz I. Komaromi R. L. Martin D. J. Fox T. Keith M. A. Al‐Laham C. Y. Peng A. Nanayakkara M. Challacombe P. M. W. Gill B. Johnson W. Chen M. W. Wong C. Gonzalez J. A. Pople Gaussian Inc. Wallingford CT 2004.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-25 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1002/chem.200901939"><img src="https://citestamp.com/citestamped/10.1002/chem.200901939/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1002/chem.200901939)